Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of once-weekly RO7795068 in Japanese adults with obesity
jRCT2061260045Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing RO7795068 once weekly with Placebo once weekly (2 arms). Primary endpoint: Percent change from baseline in body weight at Week 72. Started Oct 2026; status: recruiting.
02
Drugs
zilebesiran
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2061260045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260045.